Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. has amended its merger agreement with Power Analytics Global Corp (PAGC), setting a standalone closing valuation of $1.71 billion if the APQC Acquisition is not completed by November 1, 2026, down from the original $2.85 billion. Additionally, the company terminated its previous fairness opinion engagement and appointed Joel A. Gallo as an independent evaluator to provide a fairness opinion on the $1.71 billion standalone valuation.…more
Drugs Made In America Acquisition Corp.
DMAA has amended its merger agreement with Power Analytics Global Corp (PAGC) to automatically adjust the closing valuation from $2.85 billion to $1.71 billion if the APQC Acquisition is not completed by November 1, 2026. Additionally, the company terminated its previous fairness opinion provider and engaged Joel A. Gallo as an independent evaluator, with the opinion on the $1.71 billion valuation expected by October 26, 2026.…more
Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. (DMAA) entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp (PAGC) on September 8, 2026. The transaction fixes the closing valuation at $2.85 billion, with DMAA domesticating to Delaware and merging with PAGC to continue as a Nasdaq-listed entity. Closing is subject to conditions including a minimum of $15 million in available cash and the completion of PAGC's acquisition of APQC.…more
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
No news collected yet. New articles will appear here.